Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Neuro Stents & Coils Technology and Market Forecast
4.
Outsourcing in Drug Discovery, 3rd Edition
5.
American Hospital Register
6.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
7.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Multiple Sclerosis World Market Outlook to 2011
Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS that causes significant disability in young adults. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life.
The market for these treatments has grown 15% since 2004 and continued double-digit growth is expected in the near term. Kalorama Information's: Multiple Sclerosis: A Market Briefing takes a detailed look at multiple sclerois worldwide and the market for MS treatments, as well as treatments that will be available in the future. Kalorama's study focusing on the following four treatments:
Copaxone
Avonex
Rebif
Betaseron/Betaferon
As part of its continuing coverage, this report provides:
Overview of Multiple Sclerosis and its Progression.
Complete Incidence and Prevalence Statistics For U.S. and Worldwide.
Triggers and Risk Factors of MS.
Review of Multiple Sclerosis Treatments on the Market
Market Size and Forecasts For Treatements to 2011.
Issues and Trendsfacing MS treatment
New Multiple Sclerosis Treatments in the pipleline.
As part of Kalorama's trusted information -gathering process, intensive research into company, trade and medical literature was supplemented by interviews with experts in the multiple sclerosis treatment industry. Interviews make up the source of forecast and market size figures.
The Multiple Sclerosis market is examined for the U.S., European and Japanese markets.
Published: Jun 1, 2007
110 Pages
PDF Format
Table of Contents
Price: $2,995.00 / GBP1,497.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.